ARS Pharmaceuticals, Inc.

ARS Pharma reported second-quarter 2026 U.S. net product revenue of $26.2 million and total revenue of $33.7 million. Total operating expenses were $95.1 million, including $12.8 million in cost of goods sold, and SG&A was approximately $77.6 million. Kathy Scott said gross margin was about 62% in Q2 and a little over 64% year-to-date, with lower margin driven by reserves for short-dated product, manufacturing inefficiencies as production scales, and costs for ex-U.S. product launches. Management said gross-to-net is expected to remain around 50% or approaching 50%, and it ended Q2 with $143.8 million in cash equivalents and short-term investments. For the second half of 2026, aggregate SG&A and R&D are guided to $114 million-$126 million, including about $14 million-$16 million of stock-based compensation; cash-based SG&A and R&D are expected to be $100 million-$110 million. Management reiterated a path to cash-flow breakeven by the end of 2027.

Donn Casale said his first-quarterly CEO message is centered on three priorities: provider-targeted commercial execution, financial discipline, and pipeline expansion through CSU. He framed neffy as a prevention-based market where provider conviction, not broad consumer awareness, will drive adoption, and said the company is shifting to a more efficient model focused on high-volume prescribers and repeated field engagement. His tone was confident but measured, emphasizing that share gains should be steady quarter by quarter rather than a sudden spike.

Kathy Scott focused on the margin bridge and spending outlook. She said gross margin was about 62% in Q2 and a little over 64% year-to-date, and tied the shortfall versus future expectations to short-dated reserves, manufacturing inefficiencies, and ex-U.S. launch costs; she expects gross margin to improve over time, especially in 2027 as manufacturing scales and streamlines. Management also set a tighter expense framework: second-half 2026 aggregate SG&A and R&D of $114 million-$126 million, including $14 million-$16 million of stock-based compensation, or $100 million-$110 million on a cash basis, and noted cash and short-term investments of $143.8 million.

Analysts focused on gross-to-net, product margin pressure, field force effectiveness, payer access, and the DTC reset. Management said gross-to-net can ebb and flow by segment mix but should stay around 50%, while gross margin should improve as manufacturing scales. On access, Donn Casale said coverage is already 90% commercial and 57% without prior authorization, but the bigger issue is provider conviction; on DTC, he said the company is moving away from broad linear TV toward more efficient channels like social media and search. He also said the fully deployed sales team should help drive quarter-over-quarter gains, and that Q3 should benefit from back-to-school season, though the strategy itself is unchanged.